胃肠道恶性瘤:胰腺癌在新辅助化疗中的临床试验
Paola Barrios1,2, Akhil Chawla3,4
1Division of Surgical Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Cancer treatment and research
|August 30, 2024
概括
新辅助化疗越来越多地用于手术前胰腺腺癌. 这种方法有助于治疗早期癌症的扩散,并改善患者对化疗的耐受性,为标准治疗铺平了道路.
科学领域:
- 在瘤学瘤学.
- 手术瘤学手术瘤学
- 胃肠病学 胃肠病学
背景情况:
- 胰腺腺癌 (PDAC) 是一种高度致命的恶性瘤,治疗选择有限.
- 手术切除提供了长期存活的唯一机会,但在诊断时通常是不可行的.
- 手术后的辅助疗法改善了生存率,但仍然担心早期的微转移性疾病.
研究的目的:
- 评估胰腺腺癌中新辅助化疗的生存益处.
- 评估新辅助疗法在管理微转移性疾病中的作用.
- 探索新辅助化疗和辐射对治疗耐受性和治疗结果的影响.
主要方法:
- 对胰腺癌的新辅助疗法进行具有里程碑意义的临床试验和调查的审查.
- 分析使用单一和组合化疗方案的研究.
- 在新辅助环境中评估结合放射治疗的数据.
主要成果:
- 新辅助化疗显示在手术前治疗微转移性疾病的潜力.
- 在接受新辅助治疗的患者中观察到更好的化疗耐受性.
- 有证据表明,新辅助疗法可以提高局部胰腺癌的结果.
结论:
- 新辅助疗法正在成为胰腺腺癌的关键策略.
- 具有里程碑意义的试验支持将新辅助方法纳入标准护理.
- 进一步的研究继续完善新辅助治疗方案,以改善患者的生存率.
相关概念视频
01:29Chronic Pancreatitis II: Collaborative Care
77
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
77
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
154
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
154